Holen Sie sich die Stockscreener-App
68.51
0.06%
-0.04
Handel nachbörslich:
68.51
Schlusskurs vom Vortag:
$68.55
Offen:
$68.39
24-Stunden-Volumen:
966.90K
Relative Volume:
1.01
Marktkapitalisierung:
$3.96B
Einnahmen:
$76.81M
Nettoeinkommen (Verlust:
$-162.42M
KGV:
-22.91
EPS:
-2.99
Netto-Cashflow:
$-122.49M
1W Leistung:
-5.07%
1M Leistung:
+4.26%
6M Leistung:
-3.93%
1J Leistung:
+8.87%
1-Tages-Spanne:
$67.24
$69.67
1-Wochen-Bereich:
$66.00
$72.00
52-Wochen-Spanne:
$47.86
$94.07
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
68.51 | 3.96B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-22 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Quarterly Risk: Can Arcellx Inc maintain sales growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Bond Watch: Can Arcellx Inc be the next market leaderJuly 2025 Sector Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Guggenheim Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $120 - 富途资讯
Arcellx to present anito-cel data at 2026 Tandem Meetings By Investing.com - Investing.com Nigeria
Legend Biotech, Arcellx rise after FDA draft guidance on multiple myeloma trials - MSN
Arcellx to present anito-cel data at 2026 Tandem Meetings - Investing.com
Arcellx study: earlier CAR T cut 5-year death risk by 48% - Stock Titan
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Arcellx Stock Is Sliding Despite Future Hopes - TipRanks
Arcellx director Lubner sells $450k in ACLX stock By Investing.com - Investing.com Nigeria
Arcellx director Lubner sells $450k in ACLX stock - Investing.com
Why (ACLX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FDA Guidance Boosts Arcellx (ACLX) and Legend Biotech (LEGN) Shares - GuruFocus
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials - Seeking Alpha
Arcellx Stock Gains Momentum with New Buy Ratings - timothysykes.com
This Insider Has Just Sold Shares In Arcellx - simplywall.st
Assessing Arcellx (ACLX) Valuation After Strong Myeloma Data And Fresh Analyst Optimism - Sahm
Christopher Heery Sells 5,882 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock By Investing.com - Investing.com India
Arcellx (ACLX) CMO Heery Christopher sells $402,996 in stock - Investing.com
Positioning Arcellx for a Pivotal 2026: Anito-cel’s Differentiated Safety, Best-in-Class CAR T Launch Potential, and Undervalued Entry Point - TipRanks
Arcellx CMO Heery sells $487k in shares By Investing.com - Investing.com South Africa
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Arcellx (NASDAQ:ACLX) Insider Sells $487,197.87 in Stock - MarketBeat
Arcellx CMO Heery sells $487k in shares - Investing.com
Arcellx, Inc. Reports Increased Loss Amid Rising Expenses - MSN
Arcellx (ACLX) CMO Heery sells $393k in shares By Investing.com - Investing.com India
Christopher Heery Sells 6,131 Shares of Arcellx (NASDAQ:ACLX) Stock - MarketBeat
Arcellx (ACLX) CMO Heery sells $393k in shares - Investing.com
How Investors May Respond To Arcellx (ACLX) ESOP Shelf Filing And Upbeat Kite Collaboration Coverage - simplywall.st
Understanding Momentum Shifts in (ACLX) - Stock Traders Daily
What technical signals suggest for Arcellx Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Pharma News: Is Arcellx Inc. stock vulnerable to regulatory risksWeekly Market Summary & AI Forecasted Stock Moves - Улправда
Why Arcellx Inc. stock could benefit from AI revolution2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - Улправда
ACLX: UBS Reaffirms Buy Rating Amid Stable Price Targets | ACLX Stock News - GuruFocus
Why Arcellx Stock Is Suddenly Catching Wall Street’s Eye - TipRanks
UBS initiates Arcellx stock coverage with Buy rating, $100 price target - Investing.com Nigeria
UBS initiates Arcellx stock coverage with Buy rating, $100 price target By Investing.com - Investing.com South Africa
Arcellx shares jump on strong multiple myeloma trial results - MSN
Arcellx, Inc. (ACLX) Stock Analysis: A Biotech Innovator With 81.71% Potential Upside - DirectorsTalk Interviews
First Week of August 21st Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset - MSN
Kelonia data too early to read to Gilead, Arcellx’s anito-cel, says BMO Capital - MSN
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8% - MarketBeat
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):